Lisata Therapeutics (LSTA) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Lisata Therapeutics (LSTA) stock.

Price Target Range — 4 Quarters

Analyst Consensus — 2 Analysts

2Hold

# Analysts2

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Lisata Therapeutics Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
May 15, 2026	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	—
Jan 21, 2026	Brookline Capital	Kemp Dolliver	Downgrade	Buy→Hold	—
Aug 21, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jul 15, 2025	Brookline Capital	Kemp Dolliver	PT Raise	Buy	$20→$32
Dec 11, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Nov 21, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Sep 18, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Aug 13, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jul 19, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jul 10, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jun 14, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
May 21, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Apr 26, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Apr 25, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Mar 1, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jan 4, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Lisata Therapeutics (NASDAQ:LSTA) from Buy to Neutral.

Benzinga Newsdesk

PRO
Brookline Capital Downgrades Lisata Therapeutics to Hold

Brookline Capital analyst Kemp Dolliver downgrades Lisata Therapeutics (NASDAQ:LSTA) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
Brookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

Brookline Capital maintains Lisata Therapeutics (NASDAQ:LSTA) with a Buy and raises the price target from $20 to $32.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

Lisata Therapeutics Inc

Lisata Therapeutics (LSTA) Stock Price Target 2026

Latest Upgrades and Downgrades for Lisata Therapeutics Stock

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

PRO
Brookline Capital Downgrades Lisata Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
Brookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

Lisata Therapeutics Inc

Lisata Therapeutics (LSTA) Stock Price Target 2026

Latest Upgrades and Downgrades for Lisata Therapeutics Stock

Analyst Ratings News

PROHC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

PROBrookline Capital Downgrades Lisata Therapeutics to Hold

PROHC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PROBrookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

PROHC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PROHC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

PRO
Brookline Capital Downgrades Lisata Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
Brookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target